Background
Methods
Literature search strategy
Inclusion criteria
Data extraction
Statistical analysis
Results
Literature search and characteristics
rs12203592 | Case | Control | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
First author | Year | Country | Ethnicity | Cancer type | Source of controls | CC | TC | TT | CC | TC | TT | HWE |
Gathany [24] | 2009 | USA | Mixed | NHL | PB | 730 | 239 | 19 | 605 | 202 | 18 | 0.814 |
Wang 1 [40] | 2009 | USA | Mixed | NHL | PB | 299 | 123 | 13 | 357 | 143 | 15 | 0.882 |
Wang 2 [40] | 2009 | USA | Mixed | NHL | PB | 332 | 157 | 29 | 283 | 160 | 19 | 0.541 |
Kvaskoff [34] | 2011 | France | Caucasians | Melanoma | HB | 654 | 307 | 48 | 871 | 518 | 79 | 0.862 |
Han 1 [35] | 2011 | USA | Caucasians | Melanoma | HB | 123 | 54 | 11 | 450 | 163 | 19 | 0.369 |
Han 2 [35] | 2011 | USA | Caucasians | Melanoma | HB | 126 | 68 | 20 | 565 | 232 | 29 | 0.394 |
Pena-Chilet [32] | 2013 | Spain | Caucasians | Melanoma | PB | 398 | 121 | 19 | 242 | 101 | 19 | 0.055 |
Han 3 [35] | 2011 | USA | Caucasians | SCC | HB | 156 | 80 | 15 | 450 | 163 | 19 | 0.369 |
Han 4 [35] | 2011 | USA | Caucasians | SCC | HB | 143 | 110 | 20 | 565 | 232 | 29 | 0.394 |
Han 5 [35] | 2011 | USA | Caucasians | BCC | HB | 139 | 54 | 20 | 503 | 191 | 24 | 0.269 |
Han 6 [35] | 2011 | USA | Caucasians | BCC | HB | 174 | 81 | 19 | 565 | 232 | 29 | 0.394 |
rs872071
|
Case
|
Control
| ||||||||||
First author
|
Year
|
Country
|
Ethnicity
|
Cancer type
|
Source of controls
|
AA
|
AG
|
GG
|
AA
|
AG
|
GG
|
HWE
|
Di Bernardo 1 [27] | 2008 | UK | Caucasians | CLL | HB | 63 | 248 | 190 | 305 | 720 | 411 | 0.754 |
Di Bernardo 2 [27] | 2008 | UK | Caucasians | CLL | PB | 67 | 232 | 201 | 183 | 391 | 202 | 0.816 |
Lan [36] | 2010 | USA | Asians | CLL | HB | 21 | 36 | 12 | 602 | 534 | 127 | 0.978 |
Crowther-Swanepoel [37] | 2010 | UK | Caucasians | CLL | PB | 74 | 203 | 117 | 129 | 179 | 89 | 0.076 |
Broderick 1 [39] | 2010 | UK | Caucasians | HL | PB | 16 | 55 | 36 | 228 | 519 | 278 | 0.629 |
Broderick 2 [39] | 2010 | UK | Caucasians | HL | PB | 83 | 198 | 118 | 259 | 562 | 269 | 0.302 |
Pratt [38] | 2010 | UK | Caucasians | MM | PB | 82 | 169 | 101 | 183 | 388 | 200 | 0.846 |
Qiao [33] | 2013 | China | Asians | NHL | HB | 341 | 381 | 64 | 777 | 653 | 112 | 0.112 |
Quantitative assessment of the included studies
rs12203592 | TT vs CC | CT vs CC | Dominant model | Recessive model | Additive model | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
C/T | OR | 95% CI | Pa
| OR | 95% CI | Pa
| OR | 95% CI | Pa
| OR | 95% CI | Pa
| OR | 95% CI | Pa
|
Overall
|
1.566
|
(1.087,2.256)*
| 0.000 | 1.070 | (0.904,1.266)* | 0.000 | 1.135 | (0.941,1.368)* | 0.000 |
1.526
|
(1.107,2.104)*
| 0.001 | 1.168 | (0.981,1.392)* | 0.000 |
Source of controls
| |||||||||||||||
PB | 0.933 | (0.672,1.295) | 0.403 | 0.904 | (0.793,1.031) | 0.320 | 0.907 | (0.799,1.029) | 0.265 | 0.971 | (0.701,1.345) | 0.420 | 0.926 | (0.830,1.033) | 0.215 |
HB |
2.094
|
(1.314,3.336)*
| 0.000 | 1.203 | (0.936,1.547)* | 0.000 |
1.314
|
(1.002,1.723)*
| 0.000 |
1.959
|
(1.310,2.931)*
| 0.003 |
1.351
|
(1.058,1.725)*
| 0.000 |
Cancer type
| |||||||||||||||
Skin cancer |
1.808
|
(1.127,2.900)*
| 0.000 | 1.130 | (0.890,1.435)* | 0.000 | 1.217 | (0.935,1.584)* | 0.000 |
1.728
|
(1.145,2.608)*
| 0.000 | 1.253 | (0.983,1.596)* | 0.000 |
Melanoma | 1.315 | (0.624,2.770)* | 0.000 | 0.957 | (0.724,1.265)* | 0.009 | 1.011 | (0.715,1.431)* | 0.000 | 1.321 | (0.684,2.552)* | 0.001 | 1.057 | (0.747,1.497)* | 0.000 |
BCC |
2.511
|
(1.630,3.867)
| 0.430 | 1.085 | (0.861,1.368) | 0.668 |
1.245
|
(1.004,1.543)
| 0.996 |
2.451
|
(1.600,3.755)
| 0.383 |
1.352
|
(1.131,1.617)
| 0.644 |
SCC |
2.520
|
(1.598,3.974)
| 0.703 |
1.651
|
(1.330,2.049)
| 0.208 |
1.743
|
(1.418,2.143)
| 0.207 |
2.120
|
(1.354,3.318)
| 0.901 |
1.643
|
(1.385,1.949)
| 0.303 |
NHL | 1.074 | (0.734,1.571) | 0.677 | 0.948 | (0.820,1.096) | 0.545 | 0.960 | (0.834,1.104) | 0.734 | 1.103 | (0.756,1.608) | 0.589 | 0.979 | (0.867,1.106) | 0.914 |
Ethnicity
| |||||||||||||||
Caucasian |
1.808
|
(1.127,2.900)*
| 0.000 | 1.130 | (0.890,1.435)* | 0.000 | 1.135 | (0.941,1.368)* | 0.000 |
1.728
|
(1.145,2.608)*
| 0.000 | 1.253 | (0.983,1.596)* | 0.000 |
Mixed | 1.074 | (0.734,1.571) | 0.677 | 0.948 | (0.820,1.096) | 0.545 | 0.960 | (0.834,1.104) | 0.734 | 1.103 | (0.756,1.608) | 0.589 | 0.979 | (0.867,1.106) | 0.914 |
rs872071
|
GG vs AA
|
GA vs AA
|
Dominant model
|
Recessive model
|
Additive model
| ||||||||||
G/A
|
OR
|
95% CI
|
P
a
|
OR
|
95% CI
|
P
a
|
OR
|
95% CI
|
P
a
|
OR
|
95% CI
|
P
a
|
OR
|
95% CI
|
P
a
|
Overall
|
1.805
|
(1.402,2.323)*
| 0.002 |
1.427
|
(1.203,1.692)*
| 0.034 |
1.556
|
(1.281,1.891)*
| 0.003 |
1.432
|
(1.293,1.587)
| 0.109 |
1.349
|
(1.201,1.515)*
| 0.002 |
Source of controls
| |||||||||||||||
PB |
1.767
|
(1.244,2.511)*
| 0.003 |
1.369
|
(1.041,1.801)*
| 0.018 |
1.478
|
(1.278,1.708)*
| 0.003 |
1.443
|
(1.270,1.639)
| 0.070 |
1.329
|
(1.116,1.582)*
| 0.002 |
HB |
1.884
|
(1.212,2.930)*
| 0.037 |
1.446
|
(1.247,1.678)
| 0.255 |
1.637
|
(1.219,2.198)
| 0.058 |
1.414
|
(1.191,1.678)
| 0.215 |
1.333
|
(1.213,1.465)
| 0.069 |
Cancer type
| |||||||||||||||
CLL |
2.424
|
(1.995,2.945)
| 0.841 |
1.752
|
(1.466,2.093)
| 0.825 |
1.982
|
(1.674,2.346)
| 0.968 |
1.646
|
(1.431,1.892)
| 0.445 |
1.543
|
(1.407,1.692)
| 0.647 |
Lymphoma |
1.396
|
(1.123,1.735)
| 0.614 |
1.279
|
(1.103,1.483)
| 0.472 |
1.308
|
(1.135,1.507)
| 0.579 |
1.245
|
(1.039,1.491)
| 0.754 |
1.206
|
(1.095,1.328)
| 0.764 |
Ethnicity
| |||||||||||||||
Caucasian |
1.844
|
(1.377,2.470)*
| 0.003 |
1.418
|
(1.124,1.787)*
| 0.019 |
1.567
|
(1.214,2.023)*
| 0.003 |
1.463
|
(1.311,1.633)
| 0.115 |
1.350
|
(1.174,1.554)*
| 0.003 |
Asian |
1.451
|
(1.072,1.965)
| 0.075 |
1.380
|
(1.164,1.636)
| 0.205 |
1.390
|
(1.180,1.637)
| 0.109 | 1.233 | (0.924,1.646) | 0.167 |
1.256
|
(1.110,1.420)
| 0.071 |